aTyr Pharma (NASDAQ:ATYR) Receives “Market Perform” Rating from Leerink Partners

by · The Markets Daily

aTyr Pharma (NASDAQ:ATYR – Get Free Report)‘s stock had its “market perform” rating reissued by Leerink Partners in a research note issued to investors on Monday.

A number of other research analysts have also recently weighed in on the company. Wall Street Zen cut aTyr Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. Cantor Fitzgerald cut aTyr Pharma from an “overweight” rating to a “neutral” rating in a report on Monday. Wells Fargo & Company increased their price objective on shares of aTyr Pharma from $17.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, June 20th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of aTyr Pharma in a research report on Wednesday, June 4th. Finally, Jefferies Financial Group increased their price target on aTyr Pharma from $9.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.50.

Read Our Latest Stock Report on aTyr Pharma

aTyr Pharma Trading Down 81.5%

ATYR stock traded down $4.92 on Monday, reaching $1.12. The company’s stock had a trading volume of 106,032,806 shares, compared to its average volume of 3,282,535. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.63 and a current ratio of 5.63. The firm has a market cap of $109.26 million, a PE ratio of -1.39 and a beta of 1.01. The business has a fifty day simple moving average of $5.36 and a two-hundred day simple moving average of $4.39. aTyr Pharma has a 12-month low of $1.00 and a 12-month high of $7.29.

aTyr Pharma (NASDAQ:ATYR – Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.04). As a group, research analysts forecast that aTyr Pharma will post -0.91 EPS for the current year.

Institutional Trading of aTyr Pharma

A number of institutional investors have recently made changes to their positions in the company. Octagon Capital Advisors LP lifted its stake in shares of aTyr Pharma by 7.5% in the 2nd quarter. Octagon Capital Advisors LP now owns 3,820,000 shares of the company’s stock valued at $19,367,000 after purchasing an additional 268,000 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of aTyr Pharma by 126.1% in the 2nd quarter. Geode Capital Management LLC now owns 2,098,076 shares of the company’s stock valued at $10,639,000 after buying an additional 1,170,276 shares during the period. Woodline Partners LP purchased a new stake in shares of aTyr Pharma in the 4th quarter valued at $6,092,000. Millennium Management LLC raised its holdings in shares of aTyr Pharma by 334.5% in the 1st quarter. Millennium Management LLC now owns 1,599,041 shares of the company’s stock valued at $4,829,000 after buying an additional 1,231,052 shares during the period. Finally, Ally Bridge Group NY LLC raised its holdings in shares of aTyr Pharma by 11.0% in the 1st quarter. Ally Bridge Group NY LLC now owns 777,020 shares of the company’s stock valued at $2,347,000 after buying an additional 77,290 shares during the period. 61.72% of the stock is owned by institutional investors and hedge funds.

aTyr Pharma Company Profile

(Get Free Report)

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Recommended Stories